Puma Biotech (PBYI) Tops Q4 EPS by 1c, offers outlook

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.31, $0.01 better than the analyst estimate of $0.30. Revenue for the quarter came in at $72.2 million versus the consensus estimate of $73.55 million.

Outlook Q1 2024:

Net Product Revenue: $38 - $40 million.
Royalty Revenue: $2.5 - $3 million
License Revenue:$0 million

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Playboy to buy back 16.6M shares from Fortress at $1.05 each
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion